Technical Analysis for CRIS - Curis, Inc.

Grade Last Price % Change Price Change
grade D 1.21 2.54% 0.03
CRIS closed down 0.84 percent on Thursday, July 2, 2020, on 12 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down
Historical CRIS trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 2.54%
Outside Day Range Expansion 2.54%
Wide Bands Range Expansion 2.54%
Fell Below 20 DMA Bearish 1.68%
Narrow Range Bar Range Contraction 1.68%
NR7 Range Contraction 1.68%
Inside Day Range Contraction 1.68%
Wide Bands Range Expansion 1.68%
Oversold Stochastic Weakness 1.68%
20 DMA Support Bullish 0.00%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Curis, Inc. engages in the research, development, and commercialization of cancer therapeutics. Its principal product is Erivedge capsule for treatment of adults with basal cell carcinoma (BCC) that has spread to other parts of the body or that has come back after surgery. The company also develops Erivedge, which is in phase II clinical trial for the treatment of operable nodular BCC; CUDC-427, a small molecule that has completed phase I clinical trial to promote cancer cell death in breast cancer and other solid tumors, and hematological cancers; and CUDC-907, a small molecule, which is in phase I clinical trial for the treatment of advanced lymphoma and multiple myeloma. In addition, it develops CUDC-101 that has completed phase I dose escalation clinical trial for the treatment of refractory solid tumors; and phase I expansion trial for the treatment of breast, gastric, head and neck, liver, or non-small cell lung cancers. Further, the company develops Debio 0932 that is in phase Ib expansion study for the treatment of solid tumors; and in a phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. It has collaborations with Genentech, Inc. for the development of Erivedge; and Debiopharm S.A. for the development and commercialization of Debio 0932. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.
Cancer Drugs Surgery Solid Tumors Drug Discovery Breast Cancer Multiple Myeloma Cancer Therapeutics Hematological Cancers Protein Kinase Inhibitors Phosphoinositide 3 Kinase Inhibitor Advanced Non Small Cell Lung Cancer Refractory Solid Tumors

Is CRIS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 3.59
52 Week Low 0.62
Average Volume 4,263,633
200-Day Moving Average 1.40
50-Day Moving Average 1.00
20-Day Moving Average 1.22
10-Day Moving Average 1.22
Average True Range 0.15
ADX 41.55
+DI 45.32
-DI 18.71
Chandelier Exit (Long, 3 ATRs ) 3.14
Chandelier Exit (Short, 3 ATRs ) 1.24
Upper Bollinger Band 1.56
Lower Bollinger Band 0.88
Percent B (%b) 0.43
BandWidth 55.53
MACD Line 0.06
MACD Signal Line 0.09
MACD Histogram -0.0223
Fundamentals Value
Market Cap 169.78 Million
Num Shares 144 Million
EPS -0.50
Price-to-Earnings (P/E) Ratio -2.36
Price-to-Sales 27.52
Price-to-Book 24.84
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.30
Resistance 3 (R3) 1.30 1.27 1.28
Resistance 2 (R2) 1.27 1.24 1.27 1.27
Resistance 1 (R1) 1.22 1.22 1.21 1.22 1.27
Pivot Point 1.19 1.19 1.18 1.19 1.19
Support 1 (S1) 1.14 1.16 1.13 1.14 1.09
Support 2 (S2) 1.11 1.14 1.11 1.09
Support 3 (S3) 1.06 1.11 1.08
Support 4 (S4) 1.06